ADA-2 gene mutation in a Crohn's disease patient without response to therapy
J Gastrointestin Liver Dis
.
2024 Mar 30;33(1):134-135.
doi: 10.15403/jgld-5271.
Authors
Eylem Yaren Yılmaz
1
,
Hasan Eruzun
2
,
Ömer Küçükdemirci
3
,
Hakan Demiröz
4
,
Engin Altundağ
5
,
Ahmet Bektaş
6
Affiliations
1
Ondokuz Mayıs University, School of Medicine, Department of Internal Medicine, Samsun, Turkey. e.yaren.534@gmail.com.
2
Ondokuz Mayıs University, School of Medicine, Department of Gastroenterology, Samsun, Turkey. hasaneruzun@gmail.com.
3
Ondokuz Mayıs University, School of Medicine, Department of Gastroenterology, Samsun, Turkey. drkucukdemirci@yahoo.com.
4
Ondokuz Mayıs University, School of Medicine, Department of Gastroenterology, Samsun, Turkey. hakandemiroz.90@gmail.com.
5
Ondokuz Mayıs University, School of Medicine, Department of Medical Genetics Samsun, Turkey.
6
Ondokuz Mayıs University, School of Medicine, Department of Gastroenterology, Samsun, Turkey. abektas@omu.edu.tr.
PMID:
38554426
DOI:
10.15403/jgld-5271
No abstract available
Publication types
Case Reports
Letter
MeSH terms
Adalimumab
Crohn Disease* / diagnosis
Crohn Disease* / drug therapy
Crohn Disease* / genetics
Humans
Mutation
Treatment Outcome
Tumor Necrosis Factor-alpha
Substances
Adalimumab
Tumor Necrosis Factor-alpha